Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin

Doctor Profile

Back

Dr. Xiuying Xiao

Gastrointestinal Oncology

Chief Physician · Master’s Supervisor · MD

Dr. Xiao is executive director of the Oncology Department at Renji Hospital, standing committee member and secretary-general of the Integrative Onco-Nephrology Committee of the Chinese Anti-Cancer Association, member of the Gastric Cancer Committee of the Chinese Society of Clinical Oncology (CSCO), member of the Gastrointestinal Tumor Committee of the Chinese Research Hospital Association, member of the Thoracic Tumor Committee of the Chinese Medical Education Association, and committee member and secretary of the Oncology Branch of the Shanghai Medical Association.

Clinical Oncology

Gastric Cancer

Intestinal Cancer

NENs

20+ yrs

Experience

20+

Multi-center Clinical Trials

40+

SCI Papers

Expertise

Dr. Xiao specializes in comprehensive treatment—including chemotherapy, targeted therapy, and immunotherapy—for digestive tract and neuroendocrine tumors, as well as personalized and precise management of complex and challenging malignancies. Her research involves the basic mechanisms and translational studies of gastrointestinal tumors, including biomarker identification and resistance mechanisms, aiming to accelerate the clinical application of scientific findings.

Professional Background

Dr. Xiao has worked in the field of oncology for over 20 years, gaining extensive clinical experience in the diagnosis and treatment of gastrointestinal and neuroendocrine tumors. As a principal investigator (PI) or co-PI, she has participated in numerous domestic and international multicenter clinical trials of novel therapies, with a research focus on mechanisms of drug resistance in metastatic disease and overcoming resistance to targeted therapies. She also contributed to the compilation of oncology-related works such as Cancer Patient Rehabilitation Guidance, General Clinical Oncology, and Gastric Cancer: Translational Research from Basic to Clinical.

Awards & Honors

  • Honored with the HurunPingAn Good Doctors of China 2017
  • Recognized as a Model Physician at the 4th Yangtze River Delta Benevolent Doctor Awards
  • Recognized as Young Outstanding Worker of Xuhui District

Recent Key Publications:

  1. Lin X, Han T, Zhuo M, Liu T, Liu Z, Xiang D, Li H, Xiao X. A retrospective study of clinicopathological characteristics and prognostic factors of Krukenberg tumor with gastric origin. J Gastrointest Oncol. 2022 Jun;13(3):1022-1034. doi: 10.21037/jgo-22-464. PMID: 35837152; PMCID: PMC9274061.
  2. Lin X L , Xiao X Y , Oncology D O ,et al.Progress in neoadjuvant drug therapy of rectal cancer[J].World Chinese Journal of Digestology, 2018, 26(22):1340-1347.DOI:10.11569/wcjd.v26.i22.1340.
  3. Lin X L , Xu Q , Tang L ,et al.Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway[J].Plos One, 2017, 12(5).DOI:10.1371/journal.pone.0177335.
  4. Lin J R , Zhang Q , Cai Y ,et al.S5 Table[J].  2017.
  5. Wang L , Shen X , Wang Z ,et al.A molecular signature for the prediction of recurrence in colorectal cancer[J].Molecular Cancer, 2015, 14(1):22.DOI:10.1186/s12943-015-0296-2.
  6. Ren F , Wang L , Shen X ,et al.MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer[J].American Journal of Cancer Research, 2015.
  7. Chi Y , Wang L , Xiao X ,et al.Abnormal expression of CDK11.sup.p58.sup. in prostate cancer[J].  2014.DOI:10.1186/1475-2867-14-2.
  8. Yayun,Chi,Lisha.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014, 14(1):2-2.DOI:10.1186/1475-2867-14-2.
  9. Yayun,Chi,Lisha,et al.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014.DOI:10.1186/1475-2867-14-2.
  10. Cuenca-López, María D, Montero J C , Morales J C ,et al.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling[J].BMC Cancer,14,1(2014-04-30), 2014, 14(1):302.DOI:10.1186/1471-2407-14-302.
  11. Wang Q , Huang Z , Guo W ,et al.MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADP-Ribosylation Factor-like 5A in Human Colorectal Carcinoma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(5):1146-57.DOI:10.1158/1078-0432.CCR-13-1023.
  12. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer.[J].Journal of Translational Medicine, 2013.DOI:10.1186/1479-5876-11-151.
  13. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer[J].Journal of Translational Medicine, 2013, 11(1):151-151.DOI:10.1186/1479-5876-11-151.
  14. [13] Brusi D ,Carles Roqué, Maspla J .Fundamentos conceptuales y didácticos: Los procesos geológicos externos: las infinitas interacciones en la superficie de la Tierra[J].Plos One, 2013, 7(9):168-168.DOI:10.1371/journal.pone.0044548.
  15. [14] Wang Q , Huang Z , Ni S ,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer[J].PLoS ONE, 2012, 7(9):e44398-.DOI:10.1371/journal.pone.0044398.
  16. [15] Qifeng Wang,Zhaohui Huang,Shujuan Ni,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer.[J].PLoS ONE, 2012.DOI:10.1371/journal.pone.0044398.
  17. [16] Wang L , Xiao X , Li D ,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012, 10(1):215-215.DOI:10.1186/1479-5876-10-215.
  18. [17] Wang Q , Huang Z , Ni S ,et al.TORTS-LIABILITY OF CHARITABLE HOSPITAL FOR INJURIES TO PATIENT CAUSED BY NEGLIGENCE OF NURSE AND INTERN. [New York][J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0044398.
  19. [18] Zhu Y F , Ke H L , Guo X Z ,et al.PI3K expression and PIK3CA mutations are related to colorectal cancer metastases[J].World Journal of Gastroenterology, 2012.DOI:CNKI:SUN:ZXXY.0.2012-28-015.
  20. [19] Lisha,Wang,Xiuying,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012.DOI:10.1186/1479-5876-10-215.
  21. [20] Hui L , Xiao-Min Y , Jia-Xin W ,et al.The VNTR Polymorphism of the DC-SIGNR Gene and Susceptibility to HIV-1 Infection: A Meta-Analysis[J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0042972.
Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Doctor Profile

Dr. Xiuying Xiao

Gastrointestinal Oncology

Chief Physician · Master’s Supervisor · MD

Clinical Oncology

Gastric Cancer

Intestinal Cancer

NENs

Experience

0 +yrs
0 +

Multi-center Clinical Trials

0 +

SCI Papers

Second Opinion ＄399

Contact Me

Expertise

Dr. Xiao specializes in comprehensive treatment—including chemotherapy, targeted therapy, and immunotherapy—for digestive tract and neuroendocrine tumors, as well as personalized and precise management of complex and challenging malignancies. Her research involves the basic mechanisms and translational studies of gastrointestinal tumors, including biomarker identification and resistance mechanisms, aiming to accelerate the clinical application of scientific findings.

Professional Background

Dr. Xiao has worked in the field of oncology for over 20 years, gaining extensive clinical experience in the diagnosis and treatment of gastrointestinal and neuroendocrine tumors. As a principal investigator (PI) or co-PI, she has participated in numerous domestic and international multicenter clinical trials of novel therapies, with a research focus on mechanisms of drug resistance in metastatic disease and overcoming resistance to targeted therapies. She also contributed to the compilation of oncology-related works such as Cancer Patient Rehabilitation Guidance, General Clinical Oncology, and Gastric Cancer: Translational Research from Basic to Clinical.

Awards & Honors

Honored with the Hurun·PingAn Good Doctors of China 2017

Recognized as a Model Physician at the 4th Yangtze River Delta Benevolent Doctor Awards

Recognized as Young Outstanding Worker of Xuhui District

Professional Background

  1. Lin X, Han T, Zhuo M, Liu T, Liu Z, Xiang D, Li H, Xiao X. A retrospective study of clinicopathological characteristics and prognostic factors of Krukenberg tumor with gastric origin. J Gastrointest Oncol. 2022 Jun;13(3):1022-1034. doi: 10.21037/jgo-22-464. PMID: 35837152; PMCID: PMC9274061.
  2. Lin X L , Xiao X Y , Oncology D O ,et al.Progress in neoadjuvant drug therapy of rectal cancer[J].World Chinese Journal of Digestology, 2018, 26(22):1340-1347.DOI:10.11569/wcjd.v26.i22.1340.
  3. Lin X L , Xu Q , Tang L ,et al.Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway[J].Plos One, 2017, 12(5).DOI:10.1371/journal.pone.0177335.
  4. Lin J R , Zhang Q , Cai Y ,et al.S5 Table[J]. 2017.
  5. Wang L , Shen X , Wang Z ,et al.A molecular signature for the prediction of recurrence in colorectal cancer[J].Molecular Cancer, 2015, 14(1):22.DOI:10.1186/s12943-015-0296-2.
  6. Ren F , Wang L , Shen X ,et al.MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer[J].American Journal of Cancer Research, 2015.
  7. Chi Y , Wang L , Xiao X ,et al.Abnormal expression of CDK11.sup.p58.sup. in prostate cancer[J]. 2014.DOI:10.1186/1475-2867-14-2.
  8. Yayun,Chi,Lisha.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014, 14(1):2-2.DOI:10.1186/1475-2867-14-2.
  9. Yayun,Chi,Lisha,et al.Abnormal expression of CDK11p58 in prostate cancer[J].Cancer Cell International, 2014.DOI:10.1186/1475-2867-14-2.
  10. Cuenca-López, María D, Montero J C , Morales J C ,et al.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling[J].BMC Cancer,14,1(2014-04-30), 2014, 14(1):302.DOI:10.1186/1471-2407-14-302.
  11. Wang Q , Huang Z , Guo W ,et al.MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADP-Ribosylation Factor-like 5A in Human Colorectal Carcinoma[J].Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2014, 20(5):1146-57.DOI:10.1158/1078-0432.CCR-13-1023.
  12. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer.[J].Journal of Translational Medicine, 2013.DOI:10.1186/1479-5876-11-151.
  13. Xiao X , Wang L , Wei P ,et al.Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer[J].Journal of Translational Medicine, 2013, 11(1):151-151.DOI:10.1186/1479-5876-11-151.
  14. [13] Brusi D ,Carles Roqué, Maspla J .Fundamentos conceptuales y didácticos: Los procesos geológicos externos: las infinitas interacciones en la superficie de la Tierra[J].Plos One, 2013, 7(9):168-168.DOI:10.1371/journal.pone.0044548.
  15. [14] Wang Q , Huang Z , Ni S ,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer[J].PLoS ONE, 2012, 7(9):e44398-.DOI:10.1371/journal.pone.0044398.
  16. [15] Qifeng Wang,Zhaohui Huang,Shujuan Ni,et al.Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer.[J].PLoS ONE, 2012.DOI:10.1371/journal.pone.0044398.
  17. [16] Wang L , Xiao X , Li D ,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012, 10(1):215-215.DOI:10.1186/1479-5876-10-215.
  18. [17] Wang Q , Huang Z , Ni S ,et al.TORTS-LIABILITY OF CHARITABLE HOSPITAL FOR INJURIES TO PATIENT CAUSED BY NEGLIGENCE OF NURSE AND INTERN. [New York][J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0044398.
  19. [18] Zhu Y F , Ke H L , Guo X Z ,et al.PI3K expression and PIK3CA mutations are related to colorectal cancer metastases[J].World Journal of Gastroenterology, 2012.DOI:CNKI:SUN:ZXXY.0.2012-28-015.
  20. [19] Lisha,Wang,Xiuying,et al.Abnormal expression of GADD45B in human colorectal carcinoma[J].Journal of Translational Medicine, 2012.DOI:10.1186/1479-5876-10-215.
  21. [20] Hui L , Xiao-Min Y , Jia-Xin W ,et al.The VNTR Polymorphism of the DC-SIGNR Gene and Susceptibility to HIV-1 Infection: A Meta-Analysis[J].Plos One, 2012, 7(9):168-168.DOI:10.1371/journal.pone.0042972.

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

WhatsApp

Book Your Appointment